Literature DB >> 18791057

Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases.

T Y-T Lu1, T Jónsdóttir, T Jonsdottir, R F van Vollenhoven, D A Isenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18791057     DOI： 10.1136/ard.2008.091124

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  B cell depletion for autoimmune diseases in paediatric patients.

Authors:  Annette F Jansson; Claudia Sengler; Jasmin Kuemmerle-Deschner; Bernd Gruhn; A Birgitta Kranz; Hartwig Lehmann; Daniela Kleinert; Lars Pape; Hermann J Girschick; Ivan Foeldvari; Dieter Haffner; Johannes P Haas; Dagmar Moebius; Dirk Foell; Joachim Peitz; Veit Grote
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

2.  Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.

Authors:  John S Yi; Emily C Decroos; Donald B Sanders; Kent J Weinhold; Jeffrey T Guptill
Journal:  Muscle Nerve       Date:  2013-10-07       Impact factor: 3.217

Review 3.  B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

Authors:  Catarina Favas; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2009-12       Impact factor: 20.543

4.  JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7.

Authors:  David N Soleimani-Meigooni; Katherine E Schwetye; Maria Reyes Angeles; Caroline F Ryschkewitsch; Eugene O Major; Xin Dang; Igor J Koralnik; Robert E Schmidt; David B Clifford; F Matthew Kuhlmann; Robert C Bucelli
Journal:  J Neurovirol       Date:  2016-07-15       Impact factor: 2.643

5.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01

Review 6.  Approaches for estimating minimal clinically important differences in systemic lupus erythematosus.

Authors:  Sharan K Rai; Jinoos Yazdany; Paul R Fortin; J Antonio Aviña-Zubieta
Journal:  Arthritis Res Ther       Date:  2015-06-03       Impact factor: 5.156

7.  Off-label use of rituximab for systemic lupus erythematosus in Europe.

Authors:  Monica Rydén-Aulin; Dimitrios Boumpas; Irene Bultink; Jose Luis Callejas Rubio; Luis Caminal-Montero; Antoni Castro; Agustín Colodro Ruiz; Andrea Doria; Thomas Dörner; Cristina Gonzalez-Echavarri; Elisa Gremese; Frederic A Houssiau; Tom Huizinga; Murat Inanç; David Isenberg; Annamaria Iuliano; Søren Jacobsen; Juan Jimenéz-Alonso; Lászlo Kovács; Xavier Mariette; Marta Mosca; Ola Nived; Joaquim Oristrell; Manuel Ramos-Casals; Javier Rascón; Guillermo Ruiz-Irastorza; Luis Sáez-Comet; Gonzalo Salvador Cervelló; Gian Domenico Sebastiani; Danilo Squatrito; Gabriella Szücs; Alexandre Voskuyl; Ronald van Vollenhoven
Journal:  Lupus Sci Med       Date:  2016-09-06

8.  Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.

Authors:  Claire Trivin; Antoine Tran; Bruno Moulin; Gabriel Choukroun; Philippe Gatault; Cécile Courivaud; Jean-François Augusto; Maxence Ficheux; Cécile Vigneau; Eric Thervet; Alexandre Karras
Journal:  Clin Kidney J       Date:  2016-11-10

9.  Infectious complications of rituximab therapy in renal disease.

Authors:  Andrew Nixon; Leanne Ogden; Alexander Woywodt; Ajay Dhaygude
Journal:  Clin Kidney J       Date:  2017-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.